Parabilis Medicines, Inc. (PBLS)
$28.95+5.35%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $95M
- Beta
- 5.03
- P/E (TTM)
- -0.78
- Short % float
- 272.23%
- Days to cover
- 4.8
- SI change
- +35.6%
- 1W
- -1.96%
- 1M
- -21.50%
- vs SPY 1W
- -2.39%
- vs SPY 1M
- -23.56%
Industry peers
FMP comparable companies · ranked by market cap
- RLAYSELLRelay Therapeutics, Inc.$3.8BRECOVERYQ 3$17.41+0.56%
- TNGXSELLTango Therapeutics, Inc.$3.7BRECOVERYQ 24$22.57+1.51%
- ZYMESELLZymeworks Inc.$1.9BBEARQ 12$25.26-1.78%
- IMNMSELLImmunome, Inc.$1.8BCRISISQ 18$19.31-2.05%
- CGEMSELLCullinan Therapeutics, Inc.$950MCRISISQ 1$15.46-3.73%
- GLUESELLMonte Rosa Therapeutics, Inc.$872MCRISISQ 8$10.32+2.14%
- CTMXSELLCytomX Therapeutics, Inc.$538MCRISISQ 6$2.47-5.84%
- CBIOSELLCrescent Biopharma, Inc.$524MCRISISQ -1$14.12-3.02%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PBLS?
- LOPJLB’s latest quantitative signal on Parabilis Medicines, Inc. (PBLS) is SELL. Signals are updated daily.
- What market regime is PBLS in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Parabilis Medicines, Inc. (PBLS) do?
- Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.